⌕
4D Molecular Therapeutics · FDMT · Nasdaq
Tenet 52 · Mixed
Compare
$10.79−4.43%At closeTenet 52 · Mixed
$10.79−0.50 (−4.43%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

4D Molecular Therapeutics (FDMT) Institutional Ownership

13F filers reported holding 80.8% of 4D Molecular Therapeutics (FDMT) shares as of Sep 30, 2026, across 184 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
80.8%
Sep 30, 2026
13F filers
184
quarter ended Sep 30, 2026
13F value
$836.4M
58.5M shares
Quarter's fund flow
Mild accumulation
29 new · 17 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (29 new · 56 increased · 43 reduced · 17 closed · 39 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 184 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 49 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Oct 16, 2026Bizily ScottChief Legal OfficerAcquired · Option exercise1,635$4.14↗
Oct 16, 2026Bizily ScottChief Legal OfficerDisposed · Open-market sale1,635$12.84↗
Oct 16, 2026Bizily ScottChief Legal OfficerDisposed · Option exercise1,635Stock Option (Right to Buy)—↗
Oct 5, 2026Kirn DavidSee RemarksDisposed · Open-market sale58,061$12.92↗
Oct 5, 2026Kirn DavidSee RemarksDisposed · Open-market sale272$13.61↗
Sep 16, 2026Bizily ScottChief Legal OfficerAcquired · Option exercise1,635$4.14↗
Sep 16, 2026Bizily ScottChief Legal OfficerDisposed · Open-market sale1,635$13.65↗
Sep 16, 2026Bizily ScottChief Legal OfficerDisposed · Option exercise1,635Stock Option (Right to Buy)—↗
Sep 14, 2026Kirn DavidSee RemarksDisposed · Open-market sale58,333$13.90↗
Sep 1, 2026Bizily ScottChief Legal OfficerAcquired · Option exercise584$6.49↗
Sep 1, 2026Bizily ScottChief Legal OfficerDisposed · Open-market sale584$14.00↗
Sep 1, 2026Bizily ScottChief Legal OfficerDisposed · Option exercise584Stock Option (Right to Buy)—↗
Aug 19, 2026Kirn DavidSee RemarksAcquired · Option exercise50,000$4.14↗
Aug 19, 2026Kirn DavidSee RemarksDisposed · Open-market sale43,149$15.36↗
Aug 19, 2026Kirn DavidSee RemarksDisposed · Open-market sale25,927$16.42↗
Aug 19, 2026Kirn DavidSee RemarksDisposed · Option exercise50,000Stock Option (Right to Buy)—↗
Aug 17, 2026Bizily ScottChief Legal OfficerAcquired · Option exercise1,635$4.14↗
Aug 17, 2026Bizily ScottChief Legal OfficerDisposed · Open-market sale1,635$12.20↗
Aug 17, 2026Bizily ScottChief Legal OfficerDisposed · Option exercise1,635Stock Option (Right to Buy)—↗
Aug 13, 2026Bizily ScottChief Legal OfficerAcquired · Option exercise1,635$4.14↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of 4D Molecular Therapeutics do institutions hold?

13F filers reported holding 80.8% of 4D Molecular Therapeutics' shares as of Sep 30, 2026, across 184 filers.

How many 13F filers hold 4D Molecular Therapeutics?

4D Molecular Therapeutics was held by 184 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.